Skip to main content
EWTX logo

Edgewise Therapeutics, Inc.

EWTXNASDAQHealthcareBiotechnology

$37.19Today:- (-)1Y +153.65%

As of Oct 16, 2026 close

Market cap
$4.11B
P/E (TTM)
-
Forward P/E
-
Dividend yield
-
52-week range
$14.68$48.51
Volume (live)
-
Avg. volume (3M)
1.58M

Edgewise Therapeutics (EWTX) Balance Sheet

As of Dec 31, 2025 (end of fiscal 2025), Edgewise Therapeutics reported total assets of $552.60M and total liabilities of $30.35M. Shareholders' equity was $522.26M, up 13.7% from $459.22M a year earlier. Total debt stood at $3.99M against $530.11M in cash and short-term investments, a net cash position of $526.12M. That puts debt-to-equity at 0.01, compared with 0.01 a year earlier.

Edgewise Therapeutics Balance Sheet Analysis

Values in billions USD

Scroll to see more
Balance sheet showing assets, liabilities, and shareholders' equity for Edgewise Therapeutics, Inc. (EWTX) - Annual data in billions USD
BreakdownFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019
Period endingDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019
Current Assets
Cash and Cash Equivalents0.060.040.090.020.020.100.02
Short-Term Investments0.470.430.230.330.270.020.00
Cash & Short-Term Investments0.530.470.320.350.280.130.02
Accounts Receivable0.000.000.000.000.000.000.00
Inventory0.000.000.000.000.000.000.00
Other Current Assets0.010.010.010.010.000.000.00
Total Current Assets0.540.480.330.360.280.130.02
Non-Current Assets
Property, Plant & Equipment (Net)0.010.010.010.010.000.000.00
Other Non-Current Assets0.000.000.000.000.000.000.00
Total Non-Current Assets0.010.010.010.010.000.000.00
Total Assets0.550.490.340.370.290.130.02
Current Liabilities
Accounts Payable0.010.010.000.010.000.000.00
Short-Term Debt0.000.000.000.000.000.000.00
Accrued Liabilities0.020.020.010.010.000.00-
Other Current Liabilities0.020.020.010.010.010.000.00
Total Current Liabilities0.030.020.020.020.010.000.00
Non-Current Liabilities
Long-Term Debt0.000.000.000.000.000.160.00
Other Non-Current Liabilities0.000.000.000.000.000.000.04
Total Non-Current Liabilities0.000.000.000.000.000.160.04
Total Liabilities0.030.030.020.020.010.000.04
Stockholders' Equity
Common Stock0.000.000.000.000.000.000.00
Retained Earnings-0.55-0.38-0.24-0.14-0.08-0.03-0.02
Accumulated Other Comprehensive Income0.000.000.000.000.000.000.00
Additional Paid-in Capital1.070.840.560.490.350.000.00
Shares Outstanding0.110.090.070.060.05--
Total Stockholders' Equity0.520.460.320.350.270.13-0.02
Total Liabilities & Equity0.550.490.340.370.290.130.02

Source: Company financial statements from annual and quarterly filings. Data as of Jun 30, 2026. Data sources and methodology

Frequently Asked Questions About Edgewise Therapeutics Balance Sheet

How much debt does Edgewise Therapeutics have?

Edgewise Therapeutics had total debt of $3.99M as of Dec 31, 2025, against $530.11M in cash and short-term investments. Its debt-to-equity ratio was 0.01. Total debt was $4.74M a year earlier.

What are Edgewise Therapeutics's total assets?

Edgewise Therapeutics reported total assets of $552.60M as of Dec 31, 2025, up 13.5% from $486.82M a year earlier. Total liabilities were $30.35M.

What is Edgewise Therapeutics's shareholders' equity?

Edgewise Therapeutics's shareholders' equity was $522.26M as of Dec 31, 2025, or about $4.92 of book value per share.

What is the debt-to-equity ratio?

The debt-to-equity ratio divides a company's total debt by its shareholders' equity. It shows how much of the business is financed with borrowed money; normal levels vary widely by industry. Full definition